Tet2 deficiency drives liver microbiome dysbiosis triggering Tc1 cell autoimmune hepatitis

Tet2 缺乏导致肝脏微生物群失调,进而引发 Tc1 细胞自身免疫性肝炎。

阅读:10
作者:Surya P Pandey ,Mackenzie J Bender ,Alex C McPherson ,Catherine M Phelps ,Luzmariel Medina Sanchez ,Mohit Rana ,Lee Hedden ,Kishan A Sangani ,Li Chen ,Jake H Shapira ,Magdalena Siller ,Chhavi Goel ,Elena F Verdú ,Bana Jabri ,Alexander Chang ,Uma R Chandran ,Steven J Mullett ,Stacy G Wendell ,Aatur D Singhi ,Jeremy S Tilstra ,Joseph F Pierre ,Gavin E Arteel ,Reinhard Hinterleitner ,Marlies Meisel

Abstract

The triggers that drive interferon-γ (IFNγ)-producing CD8 T cell (Tc1 cell)-mediated autoimmune hepatitis (AIH) remain obscure. Here, we show that lack of hematopoietic Tet methylcytosine dioxygenase 2 (Tet2), an epigenetic regulator associated with autoimmunity, results in the development of microbiota-dependent AIH-like pathology, accompanied by hepatic enrichment of aryl hydrocarbon receptor (AhR) ligand-producing pathobionts and rampant Tc1 cell immunity. We report that AIH-like disease development is dependent on both IFNγ and AhR signaling, as blocking either reverts ongoing AIH-like pathology. Illustrating the critical role of AhR-ligand-producing pathobionts in this condition, hepatic translocation of the AhR ligand indole-3-aldehyde (I3A)-releasing Lactobacillus reuteri is sufficient to trigger AIH-like pathology. Finally, we demonstrate that I3A is required for L. reuteri-induced Tc1 cell differentiation in vitro and AIH-like pathology in vivo, both of which are restrained by Tet2 within CD8 T cells. This AIH-disease model may contribute to the development of therapeutics to alleviate AIH.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。